News
-
-
PRESS RELEASE
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Regentis Biomaterials reports progress on GelrinC® pivotal trial with 43 patients treated and U.S. enrollment completion expected by end of 2026, strengthens balance sheet, and expands European readiness for commercialization